Physician profile
Stacy Jean
NPI 1154965341
$8,950.99
in general payments reported to CMS, 2019-2025
63 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $427 · 2022: $1,973 · 2023: $2,814 · 2024: $2,599 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,823 · Education: $603 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,823.44 |
| Education | $602.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $648.01 | 2021-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $609.17 | 2022-2025 | Padcev, Vyloy, Veozah |
| Incyte Corporation | $490.35 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $420.73 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $373.49 | 2021-2024 | Enhertu, Calquence, Imfinzi |
| Lilly USA, LLC | $348.29 | 2022-2025 | Verzenio, Jaypirca, Mounjaro |
| Daiichi Sankyo INC. | $340.75 | 2022-2024 | Enhertu |
| Novo Nordisk INC | $329.49 | 2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $312.73 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $287.92 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $278.17 | 2021-2024 | |
| Exelixis INC. | $275.69 | 2023-2024 | Cabometyx |
| Celgene Corporation | $240.70 | 2022-2024 | Reblozyl, Pomalyst |
| Eisai INC. | $231.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.97 | 2022-2024 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $208.54 | 2023 | Yescarta |
| Seagen INC. | $180.13 | 2022-2023 | Tukysa, Adcetris |
| Aveo Pharmaceuticals, INC. | $179.28 | 2022-2023 | Fotivda |
| Jazz Pharmaceuticals INC. | $167.41 | 2021-2023 | |
| Abbvie INC. | $155.82 | 2024-2025 | |
| Puma Biotechnology, INC. | $149.94 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.71 | 2022-2024 | Hyqvia, Ninlaro, Fruzaqla |
| Acrotech Biopharma INC. | $137.94 | 2024 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.77 | 2022-2024 | Gilotrif |
| Sobi, INC | $118.15 | 2022-2024 | |
| Array Biopharma INC | $114.03 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Biotech, INC. | $107.75 | 2022-2024 | Tecvayli, Talvey, Darzalex |
| Axsome Therapeutics, INC. | $104.00 | 2025 | Auvelity |
| Dexcom, INC. | $99.87 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Alexion Pharmaceuticals, INC. | $95.97 | 2022-2024 | Ultomiris |
| Intuitive Surgical, INC. | $84.94 | 2025 | |
| Amgen INC. | $82.04 | 2021-2022 | |
| Genentech USA, INC. | $78.01 | 2022-2024 | Alecensa, Rozlytrek, Tecentriq |
| Agios Pharmaceuticals, INC. | $75.09 | 2023-2024 | Pyrukynd |
| Dova Pharmaceuticals | $74.04 | 2021 | |
| Mirati Therapeutics, INC. | $71.48 | 2023 | Krazati |
| Sumitomo Pharma America, INC. | $71.46 | 2023-2025 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $64.57 | 2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $59.44 | 2023-2024 | |
| Glaxosmithkline, LLC. | $59.02 | 2023-2024 | Ojjaara, Zejula, Jemperli |
| Dendreon Pharmaceuticals LLC | $58.10 | 2023 | Provenge |
| Rigel Pharmaceuticals, INC. | $53.81 | 2022-2024 | Tavalisse, Rezlidhia |
| Beigene USA, INC. | $53.78 | 2023 | Brukinsa |
| Epizyme, INC. | $51.96 | 2022-2024 | Onivyde |
| Myovant Sciences INC. | $51.79 | 2022 | |
| Pharmaessentia USA Corporation | $51.62 | 2023-2025 | Besremi |
| Stemline Therapeutics INC. | $48.68 | 2023-2024 | Orserdu |
| Servier Pharmaceuticals LLC | $41.46 | 2023 | |
| Deciphera Pharmaceuticals INC. | $37.54 | 2022-2023 | Qinlock |
| Taiho Oncology, INC. | $34.79 | 2022-2024 | |
| Emd Serono, INC. | $33.44 | 2021-2023 | Bavencio |
| Foundation Medicine, INC. | $24.83 | 2023 | |
| Adc Therapeutics America, INC. | $23.12 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.95 | 2022 | |
| Morphosys, US INC. | $21.33 | 2023 | Monjuvi |
| Boston Scientific Corporation | $19.88 | 2025 | Axonics |
| Xeris Pharmaceuticals, INC. | $18.95 | 2025 | Gvoke Hypopen |
| Karyopharm Therapeutics INC. | $18.21 | 2022 | |
| Immunogen, INC. | $17.63 | 2023 | Elahere |
| Alnylam Pharmaceuticals INC. | $17.08 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.48 | 2024 | Monoferric |
| Genmab U.S., INC. | $13.41 | 2024 | Epkinly |
| Phathom Pharmaceuticals, INC. | $12.76 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Jean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.